HCC1428(人乳腺腺癌细胞)
CBP60412
询 价
索取STR
产品描述
产品数据库
I. General information | |
Synonyms: | HCC1428 |
Background: | HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. This cell line was initiated on 11/4/95 and took 15 months to establish. |
Species: | Homo sapiens, human |
Tissue: | mammary gland/breast; derived from metastatic site: adenocarcinoma and pleural effusion |
Disease: | TNM stage IV, grade 4, adenocarcinoma |
Gender: | Caucasian, White, 49 years, female |
Morphology: | epithelial |
Growth Mode: | adherent |
Doubling Time: | N/A |
DNA Profile: | CSF1PO: 10 D13S317: 12 D16S539: 12,8 D5S818: 11,12 D7S820: 9 THO1: 8 TPOX: 8 vWA: 17 Cobioer’s Cell Line Authentication Service |
Culture Medium: |
RPMI-1640+10%FBS HCC1428完全培养基,# CBP60412M |
Cryopreservation medium: | 90%FBS+10%DMSO |
Antigen Expression: | N/A |
Receptor Expression: | N/A |
Oncogene: | her2/neu -, p53 - |
Genes Expressed: | HCC1428 cells are positive for the expression of Epithelial glycoprotein 2 [EGP2]; cytokeratin 19 The cells are negative for expression of Her2-neu and for expression of p53. |
Cellular Products: | N/A |
Tumor Formation: | N/A |
Comments: | An EBV transformed lymphoblastoid cell line [HCC1428 BL] from the same patient is available as ATCC CRL-2328. The homozygous deletion in the FHIT gene is retained in the lymphoblastoid line. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers. For more information, please contact Cobioer (4008-750-250). |